All In Biotech

Drug Trial Radar · NCT03498521

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 529 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

529

Actual

Start

Jul 10, 2018

Primary completion

Feb 14, 2023

Study completion Nov 7, 2024

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Foundation Medicine
First posted
Apr 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.

Conditions

  • Cancer of Unknown Primary Site

Interventions

  • AlectinibDrug

    Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

  • VismodegibDrug

    Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

  • IpatasertibDrug

    Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

  • OlaparibDrug

    Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

  • ErlotinibDrug

    Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

  • BevacizumabDrug

    Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

  • VemurafenibDrug

    Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

  • CobimetinibDrug

    Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

  • Trastuzumab Subcutaneous (SC)Drug

    Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

  • PertuzumabDrug

    Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

  • AtezolizumabDrug

    Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

  • CarboplatinDrug

    Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.

  • PaclitaxelDrug

    Paclitaxel will be administered intravenously, 175 mg/m\^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC

  • CisplatinDrug

    Cisplatin will be administered intravenously, 60-75 mg/m\^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.

  • GemcitabineDrug

    Gemcitabine will be administered intravenously, 1000 mg/m\^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.

  • EntrectinibDrug

    Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

  • IvosidenibDrug

    Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.

  • PemigatinibDrug

    Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1)Time frame: From randomization to the first occurrence of disease progression or death from any cause, until 330 PFS events were observed (approx. 4.3 years for MGT Cat 1 and 3.4 years for Chemotherapy Cat 1).

Locations

125 sites in 33 countries. Site status is shown where the registry gives one.

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • GenesisCare North Shore

    St Leonards, New South Wales, Australia

  • Icon Cancer Foundation

    South Brisbane, Queensland, Australia

  • Lkh-Univ. Klinikum Graz

    Graz, Austria

  • Lkh Salzburg - Univ. Klinikum Salzburg

    Salzburg, Austria

  • Medizinische Universität Wien

    Vienna, Austria

  • Instituto Nacional de Cancer - INCa

    Rio de Janeiro, Brazil

  • Hospital Sao Rafael - HSR

    Salvador, Estado de Bahia, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil

  • MHAT Nadezhda

    Sofia, Bulgaria

  • MBAL Serdika EOOD

    Sofia, Bulgaria

  • Bradford Hill Centro de Investigaciones Clinicas

    Recoleta, Chile

  • James Lind Centro de Investigación Del Cáncer

    Temuco, Chile

  • Clinica del Country

    Bogotá, Colombia

  • Inst. Nacional de Cancerologia

    Bogotá, Colombia

  • Oncomedica S.A.

    Montería, Colombia

  • Clinical Hospital Centre Zagreb

    Zagreb, Croatia

  • Masarykuv onkologicky ustav

    Brno, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • Fakultni Poliklinika Vseobecne Fakultni Niemocnice

    Prague, Czechia

  • Aarhus Universitetshospital

    Aarhus N, Denmark

  • North Estonia Medical Centre, Oncology and hematology Clinic

    Tallinn, Estonia

  • Helsinki University Central Hospital

    Helsinki, Finland

  • Tampere University Hospital

    Tampere, Finland

  • Ico - Paul Papin

    Angers, France

  • CHRU Besançon

    Besançon, France

  • Institut Bergonie

    Bordeaux, France

  • CRLCC-Francois Baclesse

    Caen, France

  • Centre Jean Perrin Centre Regional de Lutte Contre Le Cancer D auvergne

    Clermont-Ferrand, France

  • Centre Leon Berard

    Lyon, France

  • Institut Paoli-Calmettes

    Marseille, France

  • Institut régional du Cancer Montpellier

    Montpellier, France

  • Centre Antoine Lacassagne

    Nice, France

  • Institut Curie

    Paris, France

  • CHU Lyon - Centre Hospitalier Lyon Sud

    Pierre-Benite (Lyon), France

  • Centre Eugene Marquis

    Rennes, France

  • CHU Strasbourg Hpital Hautepierre

    Strasbourg, France

  • Hopital Foch

    Suresnes, France

Showing 40 of 125 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.